TY - JOUR
T1 - Characteristics of guillain-barre syndrome patient underwent hyperbaric oxygen therapy at lakesla 2016–2019
AU - Untari, Ni Komang Sri Dewi
AU - Kusumastuti, Kurnia
AU - Suryokusumo, Guritno
AU - Sudiana, I. Ketut
N1 - Publisher Copyright:
© 2021 Ni Komang Sri Dewi Untari, Kurnia Kusumastuti, Guritno Suryokusumo, I Ketut Sudiana.
PY - 2021/12/26
Y1 - 2021/12/26
N2 - BACKGROUND: Guillain-Barre syndrome (GBS) is considered an acute immune-mediated monophasic illness. Standard therapy includes intravenous immunoglobulin (IVIG) and/or plasmapheresis. Yet, long-standing disability remains a problem. In Indonesia, the availability and cost of these therapies are constraints. AIM: To show the capability of hyperbaric oxygen (HBO2) therapy in GBS patients who did not undergo standard therapy. HBO2 also provides healing in patients who experience delays in therapy. METHODS: Data included identity, demographic, social history, current disease history, disease progression and therapies used. Data were displayed in the form of tables and graphs. RESULTS: Twenty-five GBS patients underwent HBO2 from 2016 to 2019. The majority of patients were males aged 20-30 years, triggered by preceding diarrhea. After approximately three to ten days following HBO2, they felt their first positive changes. They walked with assistance after two to three weeks receiving HBO2 and without assistance after four to 12 weeks receiving HBO2. CONCLUSION: HBO2 administration show clinical improvement in GBS patients. HBO2 is expected to become an adjuctive therapy for GBS patients in Indonesia.
AB - BACKGROUND: Guillain-Barre syndrome (GBS) is considered an acute immune-mediated monophasic illness. Standard therapy includes intravenous immunoglobulin (IVIG) and/or plasmapheresis. Yet, long-standing disability remains a problem. In Indonesia, the availability and cost of these therapies are constraints. AIM: To show the capability of hyperbaric oxygen (HBO2) therapy in GBS patients who did not undergo standard therapy. HBO2 also provides healing in patients who experience delays in therapy. METHODS: Data included identity, demographic, social history, current disease history, disease progression and therapies used. Data were displayed in the form of tables and graphs. RESULTS: Twenty-five GBS patients underwent HBO2 from 2016 to 2019. The majority of patients were males aged 20-30 years, triggered by preceding diarrhea. After approximately three to ten days following HBO2, they felt their first positive changes. They walked with assistance after two to three weeks receiving HBO2 and without assistance after four to 12 weeks receiving HBO2. CONCLUSION: HBO2 administration show clinical improvement in GBS patients. HBO2 is expected to become an adjuctive therapy for GBS patients in Indonesia.
KW - Characteristics
KW - Guillain-Barre syndrome
KW - Hyperbaric oxygen therapy
UR - http://www.scopus.com/inward/record.url?scp=85117606679&partnerID=8YFLogxK
U2 - 10.3889/oamjms.2021.6679
DO - 10.3889/oamjms.2021.6679
M3 - Article
AN - SCOPUS:85117606679
SN - 1857-5749
SP - 1174
EP - 1179
JO - Open Access Macedonian Journal of Medical Sciences
JF - Open Access Macedonian Journal of Medical Sciences
ER -